Source: Breathe, 17 (2) 210024; 10.1183/20734735.0024-2021



Rating:

Share or cite this content

Citations should be made in the following way:
Anna C. Murphy, Claire Boddy, Peter Bradding. Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment. Breathe, 17 (2) 210024; 10.1183/20734735.0024-2021

Member's Comments

No comment yet.

Related content which might interest you: Con: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment Source: Breathe, 17 (2) 210049; 10.1183/20734735.0049-2021 Year: 2021 Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Combination therapy versus separate therapy in real-life primary care asthma patients Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015 Two therapy option in patients with uncontrolled asthma Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 Less is more: the impact of maintenance treatment adherence in severe asthma clinical trials Source: Eur Respir J, 53 (5) 1900599; 10.1183/13993003.00599-2019 Year: 2019 A digital therapy for proactively managing exacerbations and delivering therapeutic benefit to patients with moderate to severe asthma Source: International Congress 2019 – Clinical approach to asthma management Year: 2019 Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005 The patient’s role in the choice of new inhaler devices and dosing regimens for asthma and COPD: A preference study Source: International Congress 2016 – Kaleidoscope of respiratory nursing Year: 2016 Single inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses Source: International Congress 2017 – COPD management Year: 2017 Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Life-sustaining treatment preferences of patients with severe COPD Source: Annual Congress 2010 - Pulmonary rehabilitation and chronic care: new developments in interventions, assessment and care Year: 2010 Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 The parameters that may affect inhalation therapy success in elderly COPD and asthma patients Source: International Congress 2015 – Co-existing diseases and asthma Year: 2015 Cost analysis for patients with severe asthma receiving omalizumab treatment Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019 Identifying patients with severe asthma that will be benefit from biological therapy Source: Virtual Congress 2020 – Rethinking asthma Year: 2020 Macrolide therapy in asthma: limited treatment, long-term improvement Source: Eur Respir J 2009; 33: 1239 Year: 2009 Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Clinically important deterioration in advanced COPD patients using single inhaler triple therapy: results from the FULFIL study Source: International Congress 2017 – Management of COPD Year: 2017 Clinical and economic impact of an improvement in adherence based on specific attributes of single-inhaler triple therapies in COPD patients Source: International Congress 2019 – Inhalers: adherence and preference Year: 2019 Suboptimal asthma control in patients receiving long-term maintenance therapy Source: Annual Congress 2006 - The challenges of managing asthma in primary care Year: 2006